Physician profile
Stephen D Humm
NPI 1134256597
$1,581.24
in general payments reported to CMS, 2019-2025
14 companies · $58.96 in 2025
The $58.96 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $498 · 2020: $160 · 2021: $174 · 2022: $184 · 2023: $404 · 2024: $101 · 2025: $58.96.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $565.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $564.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $854.82 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $240.23 | 2019-2023 | Xifaxan, Plenvu |
| Ferring Pharmaceuticals INC. | $107.43 | 2019-2020 | |
| Genzyme Corporation | $105.67 | 2022-2025 | |
| Celgene Corporation | $68.67 | 2021-2023 | Zeposia |
| Braintree Laboratories, INC. | $41.19 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $29.94 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $24.56 | 2019-2020 | |
| Cumberland Pharmaceuticals, INC. | $20.37 | 2019 | |
| Gilead Sciences, INC. | $20.04 | 2019 | |
| Pfizer INC. | $18.38 | 2023 | |
| Janssen Biotech, INC. | $18.22 | 2019 | |
| Allergan, INC. | $17.20 | 2019 | |
| Ironwood Pharmaceuticals, INC | $14.52 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Humm listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.